Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma

Abstract

In this roundtable discussion, renowned cancer experts analyze the potential immunomodulatory capabilities of bempegaldesleukin (BEMPEG; NKTR- 214) in combination with an immune checkpoint inhibitor (CPI; anti-PD-1) in the therapeutic landscape of advanced renal cell carcinoma (aRCC) and other genitourinary cancers. The expert panel also shared their perspectives regarding the latest data from ongoing clinical trials which continue to show an encouraging efficacy and safety, risk/benefit of BEMPEG plus CPI combination.